Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Regeneron Pharmaceuticals
(NASDAQ:REGN)
Intraday
$966.53
0.23
[0.02%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$966.53
0.23
[0.02%]
Last update: 2:59PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Regeneron Pharmaceuticals Stock (NASDAQ:REGN)
Regeneron Pharmaceuticals Stock (NASDAQ: REGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 28, 2024
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Benzinga Insights
-
1 hour ago
Tuesday, March 26, 2024
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
Benzinga Insights
-
2 days ago
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Maintains $1135 Price Target
Benzinga Newsdesk
-
2 days ago
Monday, March 25, 2024
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
Vandana Singh
-
3 days ago
Regeneron shares are trading lower after the FDA issued Complete Response Letters for the company's Biologics License Application for odronextamab. The company said the only approvability issue is related to the enrollment status of the confirmatory trials.
Benzinga Newsdesk
-
3 days ago
Regeneron Says FDA Issued Complete Response Letters For Biologics License Application For Odronextamab In Relapsed/Refractory (R/R) Follicular Lymphoma And R/R Diffuse Large B-cell Lymphoma
Benzinga Newsdesk
-
3 days ago
Friday, March 22, 2024
Intellia Therapeutics On March 19, Notified Regeneron Pharmaceuticals That Co Is Opting Out Of Its Factor IX Co-Development And Co-Funding Agreement
Benzinga Newsdesk
-
6 days ago
Wednesday, March 20, 2024
Regeneron Pharmaceuticals Unusual Options Activity For March 20
Benzinga Insights
-
Mar 20, 2024, 3:16PM
Friday, March 15, 2024
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
Benzinga Insights
-
Mar 15, 2024, 4:01PM
Wednesday, March 13, 2024
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
-
Mar 13, 2024, 8:51AM
Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1115
Benzinga Newsdesk
-
Mar 13, 2024, 8:00AM
Tuesday, March 12, 2024
Bernstein Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces Price Target of $1125
Benzinga Newsdesk
-
Mar 12, 2024, 5:37AM
Monday, March 11, 2024
Bernstein Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces Price Target of $1125
Benzinga Newsdesk
-
Mar 11, 2024, 4:44PM
Regeneron Announces FDA Has Extended The Approval Of Praluent To Include Patients Aged 8 And Older With HeFH
Benzinga Newsdesk
-
Mar 11, 2024, 7:02AM
Friday, March 08, 2024
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Benzinga Insights
-
Mar 8, 2024, 10:00AM
Regeneron's EYLEA HD Shows Promise in Treating Eye Conditions, The Lancet Reports
Benzinga Newsdesk
-
Mar 8, 2024, 7:05AM
Friday, March 01, 2024
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
Benzinga Insights
-
Mar 1, 2024, 11:47AM
Tuesday, February 27, 2024
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
Benzinga Insights
-
Feb 27, 2024, 10:00AM
RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1184
Benzinga Newsdesk
-
Feb 27, 2024, 9:56AM
Monday, February 26, 2024
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Vandana Singh
-
Feb 26, 2024, 12:14PM
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
Benzinga Insights
-
Feb 26, 2024, 11:00AM
Friday, February 23, 2024
Regeneron Pharmaceuticals And Sanofi Announce That Dupixent® sBLA Has Been Accepted For FDA Priority Review For Treatment of COPD With Type 2 Inflammation
Benzinga Newsdesk
-
Feb 23, 2024, 1:40AM
Thursday, February 22, 2024
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Benzinga Insights
-
Feb 22, 2024, 3:15PM
Wednesday, February 21, 2024
Regeneron Pharmaceuticals Says Linvoseltamab BLA For Treatment Of Relapsed/Refractory Multiple Myeloma Accepted For FDA Priority Review, Target Action Date For FDA Decision Is August 22, 2024
Benzinga Newsdesk
-
Feb 21, 2024, 7:16AM
Regeneron Pharmaceuticals Says Linvoseltamab BLA For Treatment Of Relapsed/Refractory Multiple Myeloma Accepted For FDA Priority Review
Benzinga Newsdesk
-
Feb 21, 2024, 7:10AM
Tuesday, February 20, 2024
Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
Avi Kapoor
-
Feb 20, 2024, 7:59AM
Friday, February 16, 2024
Regeneron And Sanofi Announce Japan First In The World To Approve Dupixent® For Chronic Spontaneous Urticaria
Benzinga Newsdesk
-
Feb 16, 2024, 2:14AM
Monday, February 12, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Feb 12, 2024, 12:35PM
Tuesday, February 06, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
Vandana Singh
-
Feb 6, 2024, 2:05PM
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today
Benzinga Insights
-
Feb 6, 2024, 12:00PM
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Benzinga Insights
-
Feb 6, 2024, 12:00PM
Cantor Fitzgerald Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $925
Benzinga Newsdesk
-
Feb 6, 2024, 9:39AM
Monday, February 05, 2024
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?
Vandana Singh
-
Feb 5, 2024, 11:17AM
RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1110
Benzinga Newsdesk
-
Feb 5, 2024, 10:35AM
BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1082
Benzinga Newsdesk
-
Feb 5, 2024, 9:15AM
Friday, February 02, 2024
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
Vandana Singh
-
Feb 2, 2024, 2:01PM
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
Vandana Singh
-
Feb 2, 2024, 11:08AM
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
Shanthi Rexaline
-
Feb 2, 2024, 7:24AM
Regeneron Forecasts 2024 Adjusted R&D Expenses Of $4.3B-$4.5B And Adjusted SG&A Expenses Of $2.5B-$2.65B
Benzinga Newsdesk
-
Feb 2, 2024, 6:36AM
Regeneron Pharmaceuticals Q4 Adjusted EPS $11.86 Beats $10.77 Estimate, Sales $3.43B Beat $3.29B Estimate
Benzinga Newsdesk
-
Feb 2, 2024, 6:32AM
Regeneron Says European Medicines Agency Has Accepted For Review Marketing Authorization Application For Linvoseltamab For Treatment Of Relapsed/Refractory Multiple Myeloma
Benzinga Newsdesk
-
Feb 2, 2024, 6:02AM
Earnings Scheduled For February 2, 2024
Benzinga Insights
-
Feb 2, 2024, 5:28AM
Thursday, February 01, 2024
Earnings Outlook For Regeneron Pharmaceuticals
Benzinga Insights
-
Feb 1, 2024, 10:00AM
Tuesday, January 30, 2024
Regeneron Pharmaceuticals Unusual Options Activity For January 30
Benzinga Insights
-
Jan 30, 2024, 2:01PM
CORRECTION: Regeneron Ticker Is 'REGN'
Benzinga Newsdesk
-
Jan 30, 2024, 7:08AM
2seventy To Focus Exclusively On Commercialization And Development Of Abecma In Partnership With Bristol Myers Squibb And Will Sell R&D pipeline To Regeneron; Expected Annual Cost Savings ~$150M In 2024 And $200M In 2025
Benzinga Newsdesk
-
Jan 30, 2024, 7:05AM
Monday, January 29, 2024
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views
Benzinga Insights
-
Jan 29, 2024, 3:00PM
RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1076 Price Target
Benzinga Newsdesk
-
Jan 29, 2024, 12:46PM
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
Neil Dennis
-
Jan 29, 2024, 9:02AM
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
Shanthi Rexaline
-
Jan 29, 2024, 5:51AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch